Abstract:Abstract Background: Non-alcoholic steatohepatitis (NASH) and cirrhosis are major risk factors for hepatocellular carcinoma (HCC), which affects men 2-4 times more than women. In tumors Pyruvate kinase M2 (PKM2), induces aerobic glycolysis (Warburg effect) and proinflammatory and non-apoptotic cell death, ferroptosis. Raised levels of hepatic macrophage PKM2 expression are associated with poor prognosis HCC. We previously found that liver specific TGF-β/SMAD4 knockout mice develop iron deposition and hemochromatosis due to a dramatic loss of hepcidin. Moreover, Smad4+/−Sptbn1+/− mice develop gastrointestinal cancers but only in the presence of an altered microbiome. Recently, we found that liver-specific knockout of a TGF-β/SMAD3/4 adaptor protein, βII-spectrin (LSKO) blocks diet-induced NASH and HCC in mice, as well as in siRNA treated human NASH microfluidic cultures (Sci Transl Med. 2021;13(624): eabk2267). We hypothesized that βII-spectrin modulates PKM2 expression in NASH fatty liver, promoting proinflammatory cytokine release, inflammation and tumorigenesis. In addition, microbiome changes could alter hepcidin function and modulate ferroptosis. Our goal is to understand the molecular mechanism underlying PKM2 driven NASH and HCC. Methods: For our NASH mouse model, we fed SPTBN1Flox (control) and liver-specific βII-spectrin knockout (SPTBN1LSKO) mice a Western diet (WD). Body weight, total cholesterol, and triglyceride concentrations in serum were monitored, and PKM2 expression levels in the liver tissues was analyzed. SPTBN1Flox and SPTBN1LSKO mice were treated with both WD and Diethylnitrosamine (DEN) for HCC, and gut microbiome profiles were performed in these mice. To evaluate PKM2 expression in the NASH-associated HCC mouse model, immunohistochemical labeling was performed on liver tissues of these mice with PKM2-specific antibody. Inflammation, lipidosis and fibrosis were determined with H&E, Oil Red O and Sirius Red staining. Results: We found upregulation of PKM2 expression in NASH and HCC Kupffer cells (WD SPTBN1Flox mice). In contrast, PKM2 expression was markedly reduced in the liver in WD SPTBN1LSKO that blocked NASH and HCC. Interestingly, microbiome profiles were altered and TGF-β/SMAD3-regulated fibrosis as well as expression of inflammatory genes were significantly reduced in LSKO mice, compared to the NASH mice. Conclusions: Our findings suggest that the knockdown of the Smad3/4 adaptor βII-spectrin decreases PKM2 expression in Kupffer cells, thereby suppressing pro-inflammatory cytokine production, blocking NASH-associated HCC. Hepatic macrophages such as Kupffer cells and monocyte-derived macrophages could therefore play a critical role in the ferroptosis-mediated protumor immune microenvironment. In addition, our work provides new insight into potential mechanism for two disorders that affect males more than females, hemochromatosis and HCC. Citation Format: Kazufumi Ohshiro, Krishanu Bhowmick, Xiaochun Yang, Addison Klebanov, Sahara John, Dillon Voss, Adrian Krainer, Lopa Mishra. PKM2 Modulates hepatic macrophage regulation of NASH, ferroptosis and HCC through TGF-β signaling. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4854.

Therapeutic Targeting of PKM2 Ameliorates NASH Fibrosis Progression in A Macrophage-Specific and Liver-Specific Manner

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

Abstract 4854: PKM2 Modulates hepatic macrophage regulation of NASH, ferroptosis and HCC through TGF-β signaling

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

Pyruvate Kinase M2 Tetramerization Protects Against Hepatic Stellate Cell Activation and Liver Fibrosis.

Regulation of the Macrophage-Hepatic Stellate Cell Interaction by Targeting Macrophage Peroxisome Proliferator-Activated Receptor Gamma to Prevent Non-Alcoholic Steatohepatitis Progression in Mice

Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage PPARγ to prevent NASH progression in mice

Annexin A5 Regulates Hepatic Macrophage Polarization Via Directly Targeting PKM2 and Ameliorates NASH.

HSPA12A is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-mediated M1 Macrophage Polarization.

Search progress of pyruvate kinase M2 (PKM2) in organ fibrosis

Pyruvate Kinase M2 Regulates Fibrosis Development And Progression By Controlling Glycine Auxotrophy In Myofibroblasts

Activation of PKM2 Metabolically Controls Fulminant Liver Injury Via Restoration of Pyruvate and Reactivation of CDK1.

FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

Sphingosine kinase 1 aggravates liver fibrosis by mediating macrophage recruitment and polarization.

Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis

Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis

Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway

Targeting Endothelial Necroptosis Disrupts Profibrotic Endothelial–Hepatic Stellate Cells Crosstalk to Alleviate Liver Fibrosis in Nonalcoholic Steatohepatitis

Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling

Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression